Literature DB >> 12692420

Bfl-1 gene expression in breast cancer: its relationship with other prognostic factors.

Ho-Sung Yoon1, Sung-Hee Hong, Hee-Jun Kang, Byung Kyun Ko, Sei-Hyun Ahn, Joo-Ryung Huh.   

Abstract

The Bfl-1 gene, which was isolated from human fetal liver and only recently described, is a member of the Bcl-2 gene family. Reverse transcriptase-polymerase chain reaction was performed on RNA drawn from 30 breast cancer tissues to compare the expression of the Bfl-1 gene with other prognostic factors. The median relative ratio was 3.0 (range, 0.12-26.83) and the Bfl-1 gene expression rate was 36.7% (11/30). There was no statistically significant relationship between the clinicopathologic parameters of patients and the expression value of Bfl-1 gene. The level of Bfl-1 gene expression was higher in more advanced breast cancers than in early cancers. There was no significant relationship between the expression values and currently acknowledged prognostic factors, but a higher expression pattern was noticed in the groups of positive hormone receptors and negative p53 and negative c-erbB2, albeit statistically not significant. It seems that the increased expression of the Bfl-1 gene serves as a contributory factor in breast cancer, in the same way that another group of genes, the Bcl-2 family, contributes to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692420      PMCID: PMC3055024          DOI: 10.3346/jkms.2003.18.2.225

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  8 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  Expression pattern and regulation of genes differ between fibroblasts of adhesion and normal human peritoneum.

Authors:  Ujjwal K Rout; Ghassan M Saed; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-01-10       Impact factor: 5.211

3.  Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR.

Authors:  Atsunobu Sagara; Katsuhide Igarashi; Maky Otsuka; Takeshi Karasawa; Noriko Gotoh; Michiko Narita; Naoko Kuzumaki; Minoru Narita; Yoshinori Kato
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

Review 4.  Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.

Authors:  Walter Douglas Fairlie; Erinna F Lee
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

Review 5.  Last but not least: BFL-1 as an emerging target for anti-cancer therapies.

Authors:  Gaoyuan Wang; Sarah T Diepstraten; Marco J Herold
Journal:  Biochem Soc Trans       Date:  2022-08-31       Impact factor: 4.919

Review 6.  Targeting BCL2-Proteins for the Treatment of Solid Tumours.

Authors:  Meike Vogler
Journal:  Adv Med       Date:  2014-08-27

7.  Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.

Authors:  Simon Mathis Kønig; Vendela Rissler; Thilde Terkelsen; Matteo Lambrughi; Elena Papaleo
Journal:  PLoS Comput Biol       Date:  2019-12-11       Impact factor: 4.475

Review 8.  Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers.

Authors:  W Douglas Fairlie; Erinna F Lee
Journal:  Biochem Soc Trans       Date:  2021-11-01       Impact factor: 5.407

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.